BiomX Inc.
PHGE evidence brief
What we can confirm
- Market Cap:
- $5.0M
What it means
What to watch
Prepared research question
What matters most for PHGE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PHGE
BiomX Inc. (PHGE) is a Delaware corporation that, after discontinuing its lead phage therapy program in late 2025, underwent a management and strategic transformation in early 2026 to focus on building a diversified portfolio of advanced defense and security technologies [sec · filed 2026-06-29].
Key risk: Cash runway risk
Market Cap
$5.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials for BiomX Inc..
BiomX Inc. (PHGE) is a Delaware corporation that, after discontinuing its lead phage therapy program in late 2025, underwent a management and strategic transformation in early 2026 to focus on building a diversified portfolio of advanced defense and security technologies [sec · filed 2026-06-29].
- BiomX discontinued its lead phage candidate BX004 in December 2025 and its Israeli subsidiary commenced insolvency proceedings [sec · filed 2026-06-29].
- In Q1 2026, the company appointed Michael Oster as CEO and David Rokach as CFO, and adopted a new strategy focused on advanced defense and security [sec · filed 2026-06-29].
- As of June 30, 2026, BiomX reported cash & equivalents of $0.3M, total revenue of $0.3M, net income of -$3.8M, shareholders' equity of $10.9M, and total debt of $0.5M [sec].
- The company had an accumulated deficit of approximately $236.0 million as of March 31, 2026 [sec_mda · as of 2026-05-20].
- BiomX continues to see potential in BX011, its phage program for Staphylococcus aureus infections associated with diabetic foot infections [news · published 2025-12-08].
What works
- The company has a new management team and board focused on a diversified portfolio in advanced defense and security, which may open new revenue streams [sec · filed 2026-06-29].
- BiomX retains a phage program (BX011) targeting S. aureus in diabetic foot infections, indicating continued pipeline activity [news · published 2025-12-08].
- Shareholders' equity of $10.9M as of June 30, 2026 provides some balance sheet cushion despite low cash [sec].
What to weigh
- Cash & equivalents are only $0.3M as of June 30, 2026, with net income of -$3.8M, indicating very limited liquidity and ongoing cash burn [sec].
- The company has an accumulated deficit of ~$236.0M as of March 31, 2026, reflecting years of losses from legacy operations [sec_mda · as of 2026-05-20].
- The lead phage program BX004 was discontinued in December 2025 after a clinical hold and internal review, and the Israeli subsidiary entered insolvency [sec · filed 2026-06-29].
- Management's discussion notes 'substantial doubt about the Company's ability to continue as a going concern' [sec_mda · as of 2026-05-20].
From the filings
Quoted directly from source documents.
Discontinuation of BX004 and Israeli subsidiary insolvency
“In December 2025, the Company discontinued the development of BX004, its lead phage product candidate, and its former Israeli operating subsidiary, BiomX Ltd., commenced insolvency proceedings in Israel.”
SEC filings · June 29, 2026
New management and strategic direction
“In the first quarter of 2026, the Company underwent a complete transition of its management team and Board of Directors, appointed Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer, and adopted a new strategy focused on building a diversified portfolio of advanced defense,”
SEC filings · June 29, 2026
Accumulated deficit
“We have incurred an accumulated deficit of approximately $236.0 million as of March 31, 2026”
SEC MD&A · May 20, 2026
Going concern uncertainty
“These factors raise substantial doubt about the Company's ability to continue as a going concern.”
SEC MD&A · May 20, 2026
Risks & what to watch (4)›
Key risks
- Cash runway risk — Cash & equivalents of only $0.3M as of June 30, 2026, with ongoing net losses, suggests very limited operating runway [sec].
- Going concern uncertainty — Management itself raises 'substantial doubt about the Company's ability to continue as a going concern' [sec_mda · as of 2026-05-20].
- Legacy deficit burden — Accumulated deficit of ~$236.0M as of March 31, 2026, with no material revenue from operations [sec_mda · as of 2026-05-20].
- Pipeline discontinuity — Lead phage program BX004 discontinued; new defense strategy unproven and early-stage [sec · filed 2026-06-29].
What to watch
- Progress of the new defense and security strategy under CEO Michael Oster and CFO David Rokach [sec · filed 2026-06-29].
- Any updates on BX011, the remaining phage program for S. aureus in diabetic foot infections [news · published 2025-12-08].
- Cash burn rate and potential need for additional financing given $0.3M cash as of June 30, 2026 [sec].
- Resolution of the going concern uncertainty flagged in management's analysis [sec_mda · as of 2026-05-20].
Sources: Catalysts · Competitor trials · News · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run BiomX Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BiomX Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$1.2M
| Holder | Shares | Value |
|---|---|---|
| deerfield management company, l.p. | 131,272 | $493K |
| nantahala capital management, llc | 114,795 | $431K |
| ikarian capital, llc | 19,473 | $73K |
| morgan stanley | 19,100 | $72K |
| jpmorgan chase & co | 14,135 | $63K |
| jane street group, llc | 11,829 | $44K |
| barclays plc | 1,316 | $5K |
| ubs group ag | 573 | $2K |
| royal bank of canada | 251 | $1K |
| osaic holdings, inc. | 200 | $750 |
Showing top 10 of 13 institutional holders of BiomX Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 1.0%
- Days to cover
- 0.2
- Shares short
- 91,280
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PHGE short interestGovernance
Frequently asked questions
What is the AI investment thesis for BiomX Inc.?
BiomX Inc. (PHGE) is a Delaware corporation that, after discontinuing its lead phage therapy program in late 2025, underwent a management and strategic transformation in early 2026 to focus on building a diversified portfolio of advanced defense and security technologies [sec · filed 2026-06-29].
Who is the CEO of BiomX Inc.?
Mr. Michael Oster is the chief executive officer of BiomX Inc. (PHGE).
Where is BiomX Inc. headquartered?
BiomX Inc. (PHGE) is headquartered in Dover, DE, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.